Introduction
============

Intra-abdominal peritoneal adhesions continue to be a significant cause of long-term complications related to abdominal surgery. Peritoneal adhesions develop after 93-100% of upper abdominal laparotomies and after 67-93% of lower abdominal laparotomies[@B1]. They may lead to serious complications such as intestinal obstructions, infertility, chronic abdominal and pelvic pain, as well as difficult reoperations[@B2]. Current prevention is based on careful surgical techniques and the occasional use of physical barriers, but there is no substantial evidence that their use improves fertility, decreases pain, or reduces the incidence of postoperative bowel obstruction[@B3].

Peritoneal adhesions are the consequence of tissue trauma that may result from sharp, mechanical, or thermal injury during abdominal surgery. The development of adhesions involves the migration, proliferation, and/or differentiation of several cell types, including inflammatory, immune, mesothelial, and fibroblast cells[@B4]. Several studies have shown that fibroblasts from the injured peritoneum may have a crucial role in the formation of adhesion tissues[@B4]-[@B7]. Genes encoding proteins involved in cell adhesion, proliferation, migration, and protein/vesicle trafficking are differentially expressed between normal and adhesion fibroblasts[@B8]. Taken together, these results suggest that identification of the proteins produced in fibroblasts that are critical to the attachment of injured peritoneum and the development of fibrous tissue may provide novel targets for preventing peritoneal adhesion formation.

P-glycoprotein (P-gp), the product of the multidrug-resistance gene (MDR1), is a membrane-associated active transport protein that pumps cytotoxic drugs out of cells. P-gp is widely expressed in a variety of cells and limits absorption of toxins into tissues. It is well known that expression of P-gp results in increased efflux of drugs, which is the major cause of tumor cell resistance to chemotherapy[@B9]. P-gp is also a regulator of volume-activated Cl^-^ channel[@B10]. Directed mutations in the nucleotide-binding domains of the protein has shown that the transport and channel functions of P-gp are separate[@B11]. The volume-activated Cl^-^ channel has been found to be involved in cell volume regulation, cell proliferation, cell migration, apoptosis, and cell differentiation[@B12]. However, the physiological and pathological implications of P-gp regulating the volume-activated Cl^-^ channel are still unclear.

Here we demonstrate a new key role of P-gp in postoperative peritoneal adhesion formation. We show how peritoneal injury induces up-regulation of P-gp expression in peritoneal fibroblasts. We also describe the underlying mechanism by which overexpression of P-gp promotes the formation of peritoneal adhesions.

Results
=======

Up-regulation of P-gp Protein in Human and Rat Fibroblasts from Peritoneum Adhesions
------------------------------------------------------------------------------------

We assessed differences in gene expression levels between human normal and adhesion fibroblasts of several genes investigated in our other projects and related to cell proliferation, migration, and vesicle trafficking[@B13], [@B14]. Of the genes compared between primary cultured adhesion fibroblasts (AFB) and their matched normal fibroblasts (NFB), only the MDR1 gene was significantly upregulated in adhesion fibroblasts (Figure [S1](#SM1){ref-type="supplementary-material"}). Using immunohistochemistry we found that the expression of P-gp in fibroblasts of human and rat adhesion tissues was obviously higher than in those of adjacent normal tissues (Figure [1](#F1){ref-type="fig"}A-C). The higher expression of P-gp protein in human and rat cultured adhesion fibroblasts compared to matched normal fibroblasts was verified by Western blot (Figure [1](#F1){ref-type="fig"}D). Collectively, these data suggest that P-gp may contribute to postoperative peritoneal adhesion formation.

Involvement of P-gp in Rat Models of Postoperative Peritoneal Adhesion
----------------------------------------------------------------------

We next observed the effect of up-regulation of P-gp expression on peritoneal adhesion formation by reinfusion of primary cultured adhesion or normal rat fibroblasts (cells were infused into the abdominal cavities of rats with mild peritoneal injuries). Compared to the normal fibroblasts, the reinfusion of adhesion fibroblasts overexpressing P-gp resulted in more serious peritoneal adhesions of higher grade and a higher rate of adhesions (Figure [2](#F2){ref-type="fig"}A, Table [1](#T1){ref-type="table"}). We also found that knockdown of P-gp expression by intraperitoneal injections of MDR1-targeted siRNAs significantly reduced peritoneal adhesion development rates and adhesion grades induced by moderate peritoneal injury (Figure [2](#F2){ref-type="fig"}B, Table [2](#T2){ref-type="table"} and Figure [S2](#SM1){ref-type="supplementary-material"}). Together, these data demonstrate that P-gp plays a crucial role in postoperative peritoneal adhesion formation.

MDR1 Expression is Upregulated following Peritoneal Injury via the TGF-β1/Smad Signaling Pathway and Histone H3 Acetylation
---------------------------------------------------------------------------------------------------------------------------

We next tested the effects of several physical and chemical factors associated with peritoneal injury on the expression of MDR1. Only TGF-β1 up-regulated MDR1 mRNA expression and elevated P-gp expression in NFB (Figure [3](#F3){ref-type="fig"}A and Figure [S3](#SM1){ref-type="supplementary-material"}A). Both reinfusion of peritoneal fluids with high endogenous TGF-β1 and intraperitoneal injection of exogenous TGF-β1 resulted in more severe peritoneal adhesions and increased P-gp expression in adhesion tissues (Figure [3](#F3){ref-type="fig"}B-E, [Supplemental table 1](#SM1){ref-type="supplementary-material"} and 2). TGF-β type I receptor (TβRI) inhibitor SB431542 and siRNAs targeted to Smad 2 or 3 prevented induction of P-gp expression by TGF-β1 (Figure [3](#F3){ref-type="fig"}F and G). These results indicate that peritoneal injury up-regulates MDR1 expression via the TGF-β1/Smad signaling pathway.

We then investigated MDR1 transcriptional activation. ChIP assay results revealed that histone H3 and acetylated histone H3 but not Smad2/3 directly interact with the MDR1 promoter (Figure [3](#F3){ref-type="fig"}H and I). TGF-β1 promoted acetylation of histone H3, and SB431542 or Si-Smad2 abrogated the increased acetylation of histone H3 and subsequent MDR1 mRNA expression. Moreover, C646, an inhibitor of histone acetyltransferase CBP/p300 that can bind to Smad2/3[@B15], [@B16], also abolished the increased acetylation of histone H3 and MDR1 mRNA expression induced by TGF-β1 (Figure [3](#F3){ref-type="fig"}J and Figure [S3](#SM1){ref-type="supplementary-material"}B).

In order to determine whether activation of the TGF-β1/Smad signaling pathway and acetylation of histone H3 modulates the activity of the MDR1 promoter, we used a MDR1 promoter-driven luciferase gene construction (pMDR1 (-1202) plasmid). We found that pMDR1(-1202) activity was greatly increased by TGF-β1 stimulation, histone deacetylase (HDAC) inhibitor panobinostat (LBH589) treatment, co-transfection with histone H3, Smad2, or Smad3 plasmids. SB431542 and C646 blocked the increased activity induced by TGF-β1 (Figure [3](#F3){ref-type="fig"}K). Together, these results suggest that TGF-β1 enhances the activity of the MDR1 promoter and the transcription of MDR1 via the TGF-β1/Smad signaling pathway and subsequent histone H3 acetylation (Figure [3](#F3){ref-type="fig"}L).

Up-regulation of P-gp Expression Elevated Volume-activated Cl^-^Current (*I*~Cl,vol~) and Regulatory Volume Decrease (RVD) of Peritoneal Fibroblasts
----------------------------------------------------------------------------------------------------------------------------------------------------

Whole-cell chloride currents were recorded to assess the activity of the chloride channels in normal and adhesion rat fibroblasts. The currents were activated by extracellular treatment with a 47% hypotonic bath solution. The hypotonicity-activated Cl^-^ currents were eliminated by the cell shrinkage induced by the hypertonic and isotonic bath solutions, indicating that the Cl^-^ currents were volume-sensitive (Figure [4](#F4){ref-type="fig"}A and B). The reversal potential of the *I*-*V* curve was similar to the calculated E~Cl~ (-0.8 mV), with a mean value of 2.23 ± 1.8 mV (Figure [S4](#SM1){ref-type="supplementary-material"}A). The sequence of anion permeability was I^-^ \> Br^-^\> Cl^-^ \> gluconate (Figure [S4](#SM1){ref-type="supplementary-material"}B) and gluconate shifted the reversal potential at -22.85 ± 3.5 mV (Figure [S4](#SM1){ref-type="supplementary-material"}C). Silencing of ClC-3 by transfection with Si-ClC3 impaired both hypotonicity-induced Cl^-^ currents and regulatory volume decrease (RVD, Figure [S4](#SM1){ref-type="supplementary-material"}D and E). Further analysis showed that current densities were different between the NFB and AFB cells. The *I*~Cl,vol~ in the AFB was larger than in the NFB. The current densities of *I*~Cl,vol~ at +80 mV were 138.9 ± 19.9 pA/pF in AFB and 64.5 ± 7.7 pA/pF in NFB (Figure [4](#F4){ref-type="fig"}A). Furthermore, knockdown of P-gp expression by transfection with MDR1-specific shRNAs significantly inhibited the Cl^-^ currents induced by the hypotonic solution (Figure [4](#F4){ref-type="fig"}B and Figure [S5](#SM1){ref-type="supplementary-material"}).

We next compared the RVD capability between normal and adhesion rat fibroblasts. Cells swelled immediately following the hypotonic challenge, and then cell volume decreased gradually to normal levels. The extent of volume recovery was clearly different between NFB and AFB (Figure [4](#F4){ref-type="fig"}C). The capability of RVD in human and rat adhesion fibroblasts was significantly higher than in corresponding normal fibroblasts. Moreover, the transfection of cells with MDR1-specific shRNAs significantly inhibited the RVD induced by hypotonic stress in adhesion fibroblasts (Figure [4](#F4){ref-type="fig"}D). Collectively, the results indicate that P-gp may promote shape changes in adhesion fibroblasts through cell volume regulation by increasing the activity of volume-activated chloride channels.

P-gp Regulates *I*~Cl,vol~ by Promoting Phosphorylation of ClC-3 Tyrosine 342 *via* Src Tyrosine Kinase
-------------------------------------------------------------------------------------------------------

Then we investigated how overexpression of P-gp enhanced *I*~Cl,vol.~The results showed that P-gp co-localized with ClC-3, a member of the ClC voltage-gated Cl^-^ channel superfamily that may function as a key component of the volume-activated Cl^-^ channel, at the leading edge of lamellipodia and at the rear of migrating cells (Figure [S6](#SM1){ref-type="supplementary-material"}). TGF β1 stimulation induced trafficking of ClC-3 to the plasma membrane (Figure [S7](#SM1){ref-type="supplementary-material"}). Silencing of P-gp expression did not effect ClC-3 expression (Figure [S8](#SM1){ref-type="supplementary-material"}). P-gp did not directly bind to ClC-3 (Figure [4](#F4){ref-type="fig"}G) but promoted phosphorylation of human ClC-3 tyrosine 342 (Figure [4](#F4){ref-type="fig"}E), which has been found to be an important molecular mechanism for volume-activated Cl^-^ channel activation[@B17]. Moreover, we found that both hypotonicity and TGF β1 stimulation induced ClC-3 tyrosine 342 phosphorylation. Silencing of P-gp expression by transfection with Si-MDR1 or treatment with Src kinase inhibitor SU6656 abolished the increased phosphorylation of ClC-3 tyrosine induced by either hypotonicity or TGF β1 (Figure [4](#F4){ref-type="fig"}E). Phosphorylation of the Src activation residue Tyr416 was elevated in adhesion fibroblasts when compared to normal fibroblasts. Both hypotonicity and TGF β1 treatment increased phosphorylation of Src Tyr416 but did not effect Src kinase expression. Silencing of P-gp expression blocked the increased activity induced by either hypotonicity or TGF-β1 (Figure [4](#F4){ref-type="fig"}F). A co-immunoprecipitation (co-IP) assay revealed that P-gp interacts with Src kinase in NIH3T3 cells (Figure [4](#F4){ref-type="fig"}G). Together, these results suggest that overexpression of P-gp activates Src kinase by binding to the kinase and inducing phosphorylation of Src Tyr416.

Inhibition of *I*~Cl,vol~ and RVD by Cl^-^ Channel Blockers Prevents Formation of Peritoneal Adhesions and Reduces Migration and Proliferation of Adhesion Fibroblast
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

To verify that enhanced *I*~Cl,vol~ and RVD are involved in postoperative peritoneal adhesion formation, we determined the effects of Cl^-^ Channel blockers on peritoneal adhesion formation, and *I*~Cl,vol~ and RVD of adhesion fibroblasts. Tamoxifen, a well-known inhibitor of volume-activated Cl^-^ channels[@B18], mitigated the formation of rat peritoneal adhesions in a dose-dependent manner, with an IC~50~ of 3.61 mg/kg (Figure [5](#F5){ref-type="fig"}A,Table [3](#T3){ref-type="table"}). Tamoxifen (20 µM) almost completely inhibited *I*~Cl,vol~ and RVD induced by hypotension in rat AFB (Figure [5](#F5){ref-type="fig"}B, C, E-G). DCPIB, another *I*~Cl,vol~, blocker[@B19], also significantly mitigated postoperative peritoneal adhesion formation in rats and inhibited *I*~Cl,vol~ and RVD of AFB (Figure [5](#F5){ref-type="fig"}C-G, Table [4](#T4){ref-type="table"}). Moreover, the inhibition of the transport function of P-gp by tariquidar, a third generation inhibitor of P-gp transport[@B20], had no effect on postoperative peritoneal adhesion formation, *I*~Cl,vol~, or RVD (Figure [S9](#SM1){ref-type="supplementary-material"}A, Figure [5](#F5){ref-type="fig"}D and G, [Supplemental table 3](#SM1){ref-type="supplementary-material"}). However, another P-gp transport function inhibitor verapamil reduced peritoneal adhesion formation and inhibited *I*~Cl,vol~ and RVD (Figure [S9](#SM1){ref-type="supplementary-material"}B, Figure [5](#F5){ref-type="fig"}D and G, [Supplemental table 4](#SM1){ref-type="supplementary-material"}). In addition, tamoxifen, DCPIB, tariquidar, and verapamil had similar effects on migration and proliferation of adhesion fibroblasts (Figure [6](#F6){ref-type="fig"}D and G). Together, these results provide additional evidence for the roles of *I*~Cl,vol~ and RVD in the mediation of P-gp in postoperative peritoneal adhesion formation.

Up-regulation of P-gp Expression Promotes Migration and Proliferation of Peritoneal Fibroblasts
-----------------------------------------------------------------------------------------------

We next determined whether altering P-gp expression affected fibroblast migration and proliferation. As shown in Fig. [6](#F6){ref-type="fig"}A, B, E and F, compared to normal fibroblasts, the adhesion fibroblasts with high P-gp expression had higher potential for migration and proliferation. In contrast, down-regulation of P-gp expression by transfection of si-MDR1 significantly inhibited the migration and proliferation of adhesion fibroblasts (Figure [6](#F6){ref-type="fig"}C, D and G). Taken together, these data indicate that the mechanisms through which P-gp contributes to postoperative peritoneal adhesion formation are closely related to the acceleration of fibroblast migration and proliferation.

Discussion
==========

Several genes and proteins have been reported to be differentially expressed between fibroblasts of normal and adhesion peritoneum[@B4], [@B8]. However, it remains unknown how these genes or proteins contribute to peritoneal adhesion formation. This study demonstrates that the MDR1 gene encoding P-gp plays a critical role in postoperative peritoneal adhesion formation. Four lines of evidence support this notion. First, expression of P-gp protein was significantly upregulated in fibroblasts of human and rat adhesion tissues when compared to adjacent normal tissues. Second, fibroblasts derived from adhesions, as opposed to nearby peritoneum, were characterized by increased basal expression of MDR1 mRNA and P-gp protein. Third, reinfusion of adhesion fibroblasts overexpressing P-gp resulted in more serious peritoneal adhesions. Finally, knockdown of P-gp expression by intraperitoneal transfection of MDR1-targeted siRNA significantly reduced the peritoneal adhesion development rate and adhesion grades. Our results also indicate that P-gp may be a valuable therapeutic target to prevent postoperative peritoneal adhesion formation.

A crucial process during peritoneal adhesion formation is the infiltration of the fibrinous coagulum by proliferating fibroblasts followed by vascularization and cellular growth[@B21]. The high capability of peritoneal fibroblasts to proliferate and migrate would accelerate adhesion formation or increase the grade of adhesions. P-gp promotes transendothelial migration of antigen-presenting dendritic cells and T lymphocytes during an immune response[@B22]. In addition, P-gp overexpression has been shown to enhance brain endothelial cell (EC) migration[@B23]. P-gp knockdown by MDR1-targeted siRNA decreased the rate of migration in breast cancer MCF-7 cells[@B24]. Although some reports have found relationship or a negative correlation between P-gp expression and proliferation in peripheral T-cells[@B25] and some cancer cells[@B26], [@B27], other studies have demonstrated that P-gp enhances cell proliferation in normal[@B28] and cancer cells[@B29]. Our results revealed that adhesive fibroblasts overexpressing P-gp had higher potential for migration and proliferation and knockdown of P-gp inhibited cell migration and proliferation. Taken together, these results suggest that P-gp mediates postoperative peritoneal adhesion formation by promoting the migration and proliferation of peritoneal fibroblasts.

Our results also revealed that, among several physical and chemical factors associated with peritoneal injury[@B30], TGF-β1 was the inducing factor for up-regulating expression of P-gp. TGF-β1 is a major secretory product of macrophages. Macrophages are normal cellular components of reproductive tract tissues and peritoneal fluid. Excessive TGF-β1 secretion by macrophages following operative injury plays an important role in intraperitoneal adhesion formation via the Smad 2/3 signaling pathway, stimulating increased expression of plasminogen activator inhibitor (PAI)-1 and decreased expression of tissue-type plasminogen activator (t-PA)[@B31]-[@B33]. Consistent with previous studies, we also found that the concentration of TGF-β1 in peritoneal fluid was significantly higher following peritoneal injury. Both reinfusion of peritoneal fluid with high endogenous TGF-β1 and intraperitoneal injection of exogenous TGF-β1 resulted in more severe peritoneal adhesions. Interference in TGF-β1/Smad signaling by inhibitors or siRNAs mitigated the up-regulation of P-gp expression. This suggests that peritoneal injury induces elevation of P-gp expression via the TGF-β1/Smad signaling pathway.

Moreover, our results showed that Smad2/3 did not directly regulate transcription of MDR1. Instead, its activity was directly modulated by acetylated histone H3 bound to the MDR1 promoter. Histone acetylation has been found to be involved in TGF-β1-mediated induction of PAI-1 and p21 expression[@B32]. Our results revealed that TGF-β1 promoted acetylation of histone H3 and the activity of the MDR1 promoter. Inhibitors or siRNAs targeting the TGF-β1/Smad signaling pathway abrogated the increased acetylation of histone H3, the activity of the MDR1 promoter, and MDR1 mRNA expression. Smad2/3 can recruit and activate histone acetyltransferase CBP/p300, which enhances histone acetylation[@B16], [@B34]. We found that inhibition of CBP/p300 by C646 prevented the acetylation of histone H3 and induction of MDR1 mRNA expression by TGF-β1. These results indicate that histone H3 acetylation induced by CBP/p300-mediated transcription of MDR1 is downstream of the TGF-β1/Smad signaling pathway. Therefore, targeting the activity of CBP/p300 or acetylation of histone H3 may be a feasible strategy for preventing P-gp-mediated postoperative peritoneal adhesion formation.

P-gp is a bifunctional protein with a transport function that pumps cytotoxic drugs out of cells and a channel-related function that regulates volume-activated Cl^-^ channel activity[@B11]. The transport and channel-related functions of P-gp are regulated by different phosphorylation sites[@B35]. Based on our results, only the channel-related function of P-gp is involved in peritoneal adhesion formation. Although it is well known that P-gp regulates volume-activated Cl^-^ channels[@B36], the underlying mechanism remains unknown. Based on our results, P-gp enhanced phosphorylation of human ClC-3 tyrosine 342 (or tyrosine 284 in the rat ClC-3 channel). The later has been reported to be an important molecular mechanism for volume-activated Cl^-^ channel activation[@B17]. We found that P-gp did not bind to ClC-3 and it appeared that P-gp did not directly phosphorylate ClC-3. Activation of Src kinase activity leads to inhibition of P-gp transport function[@B37]. Src kinase is rapidly activated and phosphorylates ClC-3 tyrosine 342 during hypotonic stimulation[@B17]. Using immunoprecipitation and immunofluorescence staining techniques, Li et al. demonstrated that P-gp interacts with Src kinase in cancer cells (AACR Annual Meeting presentation abstract, Apr 21, 2015). Our results revealed that P-gp activates Src kinase by binding to the kinase and inducing phosphorylation of Src Tyr416. Therefore, in adhesion fibroblasts increased levels of P-gp, induced by TGF-β1, results in activated Src kinase, which then inhibits its transport activity. Activated Src kinase then phosphorylates ClC-3 tyrosine 342, which results in the opening of volume-activated Cl^-^ channels.

Volume-activated Cl^-^ current (*I*~Cl,vol~) plays a role in cell migration in several types of cells by controlling changes in cell shape during migration[@B38]-[@B40]. The opening of the ClC-3 channel facilitates the retraction of the rear of migrating cells by inducing cell shrinkage[@B41]. Our data show that P-gp co-localized with ClC-3 at the rear of migrating cell and indicate that P-gp may modulate retraction in migrating cells via*I*~Cl,vol~and RVD by phosphorylating ClC-3. Of interest, we also found that P-gp co-localized with ClC-3 at the leading edge of lamellipodia. Although ClC-3 has found to be localized at the leading edge of lamellipodia in human glioma cells, the functional implications remain unclear[@B42]. We speculate that in coordination with other ion channels and transporters, P-gp may be involved in the increase in local volume before protrusion of lamellipodium and/or the decrease following protrusion through regulation of *I*~Cl,vol~ [@B43]. This may also contribute to the promoting effects of P-gp on migration of dendritic cells and cancer cells[@B22], [@B24]. *I*~Cl,vol~ has also been shown to contribute to cell proliferation via modulation of cell volume during cell cycle progression[@B12], [@B44]. In particular, *I*~Cl,vol~ is important for the G1/S phase transition and cell division in the M-phase[@B45], [@B46]. Thus, P-gp may promote cell migration and proliferation of fibroblasts via *I*~Cl,vol~and RVD through ClC-3 phosphorylation.

Based on our results, we proposed a four-step model by which P-glycoprotein mediates postoperative peritoneal adhesion formation (Figure [7](#F7){ref-type="fig"}). First, operative injury induces excessive TGF-β1 secretion by macrophages[@B33], [@B47]. Second, TGF-β1 up-regulates P-gp expression by enhancing the activity of the MDR1 promoter via the TGF-β1/Smad signaling pathway and histone H3 acetylation. Third, P-gp accelerates activation of volume-activated Cl^-^ channels and cell RVD capability by promoting phosphorylation of ClC-3 *via* Src tyrosine kinase. Fourth, increased *I*~Cl,vol~ and cell volume regulation capability accelerates cell migration and proliferation of fibroblasts, which finally leads to peritoneal adhesion formation.

Materials and Methods
=====================

Human Peritoneal Tissue Collection and Peritoneal Fibroblast Culture
--------------------------------------------------------------------

Tissues were collected during abdominal surgery from patients who had undergone previous abdominal surgery. All samples were collected in accordance with the guidelines of the Guangdong Pharmaceutical University Institutional Review Board and informed consent was obtained from all patients. Peritoneal adhesion tissues were obtained from the adhesive band. Normal parietal peritoneal tissues near to the site of adhesive tissue collection were also collected from the same patient.

Primary culture of peritoneal fibroblasts was performed as previously described[@B4]. Briefly, the tissue samples were cut into smaller pieces (1-2 mm^2^) in a sterile culture dish and transferred into a fresh T-25 flask for primary explant culture in a humidified chamber at 37°C and 5% CO~2~. Cells were grown in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 µg/ml streptomycin. Outgrowth of fibroblasts generally took 2 weeks. When confluence was reached, the cells were subcultured by trypsinization to a maximum of 12 passages. Cells were verified as being fibroblasts by immunofluorescence with a monoclonal antibody against vimentin (1:100, Boster, Beijing, China).

Induction of Adhesions via Peritoneal Injury
--------------------------------------------

All animal studies were conducted with institutional Animal Care and Use Committee approval. Animals received no food for at least 12 hours before surgery. The rats were prepared for surgery with an injection of ketamine (80 mg/kg i.m.) anesthesia. After hair removal, the abdomen was cleansed with 1% antiseptic povidone-iodine solution and a 3 cm midline laparotomy was performed. The cecum was exposed and kept moist. Moderate injury of peritoneum on two parts of the cecum, the left and right sides of the abdominal incision, by clamping 4 times with Hemostatic forceps at a locking tension of three. For mild peritoneal injury, Hemostatic forceps at a locking tension of two were used to clamp the aforementioned cecum peritoneum three times and the abdominal peritoneum one time. Blockers were injected intraperitoneally every day for 2 weeks after the injury. Induction of adhesions by talc powder was performed as described previously[@B48].

At two weeks after the surgery, the animals were sacrificed and the abdominal cavity was opened. Adhesions were evaluated according to the Mazuji classification[@B49]. Adhesions were graded from 0 (absent) to 4 (severe). In general, Grades 0 and 1 have no clinical significance, whereas Grades 3 and 4 can cause intestinal obstruction. Adhesion rate described the presence of an adhesion of any grade.

Immunohistochemistry and Immunofluorescence
-------------------------------------------

Immunostaining was performed on tissues using the MaxVision™ two-step system (KIT-5010; Maixin Biotechnology Co., Ltd., Fuzhou, China) following the manufacturer\'s protocol. The mean optical intensity of the specific immunohistochemical staining reaction was evaluated by IPP6.0 image analysis software. Immunofluorescence was performed as described previously[@B50]. Samples were incubated overnight at 4°C with primary antibodies against P-gp (1:100, Boster) and ClC- 3 (1:50, Abcam). A Nikon Eclipse C1 confocal laser scanning microscope (Nikon Corporation, Tokyo, Japan) was used to take a series of images in the z-axis and reconstruct the three-dimensional profile.

Real-time PCR Analysis
----------------------

Total RNA was extracted from cells using Trizol (LifeTechnologies, Grand Island, NY) and subjected to reverse transcription with the ReverTra Ace-a-kit (Toyobo, Osaka, Japan) according to the manufacturer\'s instructions. Real-time PCR was performed on an Opticon 2 Real Time Cycler (BioRad, Hercules, CA) with SYBR Green PCR Master Mix kit (Toyobo, Osaka, Japan). PCR conditions consisted of a 30 second hot start at 95°C, followed by 40 cycles of 5 seconds at 95°C and 30 seconds at 60°C. The primer sequences for human MDR1 (ABCB1) mRNA were as follows: 5′-GGAAAAGAAACCAACUGUC-3′ (forward) and 5′-GACAGUUGGUUUCUUUUCC-3′ (reverse). The primer sequences for rat MDR1 (MDR1a and MDR1b) mRNA were as follows: 5′-CCCAAGATCCTTTTGTTGGA-3′ (forward) and 5′- CAAGCGGTGAGCTATCACAA -3′ (reverse).

Immunoprecipitation, Co-Immunoprecipitation, and Western blotting
-----------------------------------------------------------------

Whole-cell lysates were prepared using M-PER mammalian protein extraction reagent (Pierce, Rockford, IL). cOmplete Protease Inhibitor and PhosSTOP Phosphatase Inhibitor cocktail (Roche, Indianapolis, IN) were added fresh to the lysis buffer. For immunoprecipitation, Sepharose® Bead Conjugated Flag antibody (5750, Cell Signaling Technology, Beverly, MA) was added to the cell lysates. Precipitation was performed by overnight shaking at 4°C. Then complexes were carefully washed, and proteins were electrophoretically separated by SDS-PAGE followed by Western blotting detection using mouse monoclonal anti-phosphotyrosine antibodies (PY20; Biolegend). For co-immunoprecipation, the Pierce Co-Immunoprecipitation Kit (26149, Pierce; Rockford, Illinois, USA) was used according to the manufacturer\'s instructions. Cell Signaling Flag antibody (8146) and GeneTex P-gp antibody (C219, specific reactivity to human, mouse and rat, GTX23364) or Biolegend cytokeratin 18 (Poly6172, 617202) were used for immunoprecipitation and immunoblotting, respectively. A total of 50 µg of the primary antibody was immobilized on the affinity columns. Lysates pre-cleared with the control resin were loaded onto columns containing immobilized antibodies covalently linked to an amine-active resin and incubated under constant agitation for 12 h at 4°C. The co-immunoprecipitate was then eluted and analyzed by SDS-PAGE and Western blotting along with the input controls. Western blotting was performed as previously described[@B14]. Blots were digitally photographed, and blot density was determined using a Bio-Rad Imaging Densitometer Quantity One 4.1.0 (Bio-Rad, Hercules, California).

Chromatin Immunoprecipitation (ChIP) Assays
-------------------------------------------

To determine whether acetylated histone H3 was present at the MDR1 promoter region, we performed ChIP assays according to the manufacturers\' protocols (SimpleChIP® Enzymatic Chromatin IP Kit for Histone H3, Cell Signaling Technology; EpiQuik Acetyl-Histone H3 ChIP Kit for acetylated histone H3, Epigentek). For histone H3, cells were incubated in 1% formaldehyde to cross-link the DNA and proteins. Chromatin was sheared by sonication. Samples were incubated with Histone H3 (D2B12) XP®, Smad2/3 Rabbit mAb (Cell Signaling Technology), or with an equivalent amount of normal IgG (anti-Rabbit). A portion of the sonicated DNA was left untreated to serve as the input control. For acetylated histone H3, chromatin in the cells was extracted, sheared, and added into a microwell immobilized with the antibody. The acetyl-histone H3 protein-DNA complex was captured by the antibody, and then the DNA was released and purified through the specifically designed Fast-Spin Column. Eluted DNA was used for real-time PCR analysis. Immunoprecipitated or eluted DNA was subjected to quantitative real-time PCR using primers specific to the MDR1 promoter[@B51] (forward: 5′- TTTGCCACAGGAAGCCTGA-3′, reverse: 5′-AAAGGAAACGAACAGCGGC-3′). Signals were expressed as a percent of the total input chromatin.

Luciferase Assays
-----------------

For MDR1 promoter-luciferase transcriptional assays, cells were transiently transfected with MDR1-luc plasmid (pMDR1-1202, Addgene plasmid 37627) following treatment with different blockers or co-transfected with pMDR1-1202 and histone H3, Smad 2 or Smad 3 vectors. Then cells were assayed for luciferase and renilla activity using the Dual-Luciferase®Reporter Assays System (E1910, Promega, Milwaukee, WI) and Varioskan Flash (Thermo Fisher Scientific, Waltham, MA, USA). All experiments were performed in triplicate and normalized for renilla activity.

Additional Methods
------------------

Detailed methodology is described in the Supplementary Methods.

Supplementary Material
======================

###### 

Supplemental Methods, Supplemental Figures and Tables.

###### 

Click here for additional data file.
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![**High Expression of P-gp Protein in Human or Rat Fibroblasts of Adhesion Peritoneum.** (A and B) Representative immunohistochemical images for P-gp, a-SMA, vimentin, and collagen I in human (A) and rat (B) peritoneal adhesion tissues and adjacent normal peritoneum tissues. (C) Quantitative analysis of immunohistochemical results indicates that P-gp is highly expressed in the adhesion fibroblasts (AFB). (D) Western blot analysis shows that the P-gp protein expression was significantly upregulated in cultured human and rat AFB. \*\* *P*\< 0.01. See also Figure [S1](#SM1){ref-type="supplementary-material"}.](thnov06p0204g001){#F1}

![**Overexpression or Knockdown of P-gp Promotes or Degrades Peritoneal Adhesion in a Rodent Model, Respectively.**(A) Promotion of peritoneal adhesion formation following mild peritoneal injury and reinfusion of rat adhesion fibroblasts overexpressing P-gp into peritoneal cavity (For detailed statistical results, see Table [1](#T1){ref-type="table"}). (B) Knockdown of P-gp expression by intraperitoneal injection of MDR1 siRNAs reduced peritoneal adhesion development rate and adhesion grades induced by moderate peritoneal injury (For detailed statistical results, see Table [2](#T2){ref-type="table"}). Gene silencing efficiency of siRNA targeting MDR1 is shown in Figure [S2](#SM1){ref-type="supplementary-material"}.](thnov06p0204g002){#F2}

![**TGF-β1 Up-regulated MDR1 Expression by TGF-β1/Smad Signaling Pathway and Histone H3 Acetylation.**(A) The effect of physical factors, cytokines and growth factors associated with peritoneal injury on MDR1 mRNA expression in NFB. (B and C) Reinfusion of peritoneal fluid obtained from rats with peritoneal adhesions resulted in more serious peritoneal adhesions. (B) Peritoneal injury increased the concentration of TGF-β1 in peritoneal fluid, which reached the highest level at day 7. (C) Representative photographic images of rat peritoneal adhesions. Peritoneal fluid with high endogenous TGF-β1 was reinfused into peritoneal cavities of rats with mild peritoneal injuries, resulting in more serious peritoneal adhesions of higher grade and a greater rate of adhesions (For detailed statistical results, see [Supplemental Table 1](#SM1){ref-type="supplementary-material"}). (D and E) TGF-β1 promoted peritoneal adhesion formation and P-gp expression of adhesion tissue. (D) Representative photographic images of rat peritoneal adhesions. Intraperitoneal injection of exogenous TGF-β1 (150 ng/kg) induced more serious peritoneal adhesions of higher grade and a greater rate of adhesions (For detailed statistical results, see [Supplemental Table 2](#SM1){ref-type="supplementary-material"}). (E) Intraperitoneal injection of TGF-β1 upregulated P-gp expression in adhesion tissues. \*\* *P*\< 0.01 *vs* Control. (F and G) Inhibition of the TGF-β1/Smad pathway prevented induction of P-gp expression by TGF-β1. (F) TGF-β type I receptor (TβRI) inhibitor SB431542 inhibited P-gp expression induced by TGF-β1. (G) Silencing of Smad 2 or 3 expression by transfection with Si-Smad 2 or -Smad 3, respectively, prevented induction of P-gp expression by TGF-β1. (H - K) TGF-β1 enhances activity of the MDR1 promoter via the TGF-β1/Smad signaling pathway and promotion of histone H3 acetylation. Chromatin immunoprecipitation (ChIP) analysis of the binding of Smad2/3 and histone H3 to the MDR1 promoter in AFB (H) and acetylated H3 at the MDR1 promoter in rat NFB and NIH3T3 cells treated with TGF-β1 (I). RPL30 was used as a positive control. (J) Detection of global acetylated histone H3 in rat NFB treated with different factors. (K) Induction of MDR1 promoter activity by co-transfection with either histone H3, Smad 2, or Smad 3 expression plasmids plus pMDR1(-1202) reporter plasmid and TGF-β1 or the histone deacetylase (HDAC) inhibitor panobinostat (LBH589). TGF-β type I receptor (TβRI) inhibitor SB431542 and histone acetyltransferase CBP/p300 inhibitor C646 abolished the increased activity induced by TGF-β1. \* *P*\< 0.05; \*\* *P*\< 0.01. (L) Schematic model depicting the proposed mechanism of up-regulation of MDR1 expression induced by TGF-β1 via the TGF-β-Smad signaling pathway and histone H3 acetylation.](thnov06p0204g003){#F3}

![**Up-regulation of P-gp Expression Elevated *I*~Cl,vol~ and RVD of Peritoneal Fibroblast by Phosphorylating Chloride Channel-3 (ClC-3) tyrosine 342 *via* Src Tyrosine Kinase.** (A) Comparison of volume-activated chloride currents in AFB and NFB. Iso, isotonic bath solution; Hypo, 47% hypotonic bath solution; Hyper, 47% hypertonic bath solution. (B) Suppression of MDR1 expression by sh-MDR1 transfection on *I*~Cl,vol~ in AFB. Cells successfully transfected with sh-MDR1 or sh-NC (green) were selected for whole-cell current recordings under the fluorescence microscope. (C and D) Differential capability of RVD in AFB and NFB and inhibition of RVD by silencing of MDR1 expression in AFB. (C) Changes in AFB and NFB cell volumes in isotonic (Iso) and 47% hypotonic (Hypo) bath solutions and RVD capacity in the hypotonic bath solution. (D) RVD capacity of AFB after treatment with Sh-NC or Sh-MDR1 (n = 20). (E) P-gp promoted phosphorylation of human ClC-3 tyrosine 342. (left panels) NIH-3T3 cells were co-transfected with human MDR1-GFP vectors and ClC-3-Flag or ClC-3-Y432F. Immunoblots of IP with anti-phosphotyrosine and anti-ClC-3 antibodies from extracts of NIH-3T3 cells were probed with an antibody against Flag. (right panels) Effects of down-regulation of P-gp expression or inhibition of Src kinase by SU6656 on phosphorylation of human ClC-3 tyrosine induced by TGF β1 and hypotension. pTyr: phosphotyrosine. \*\*: *P*\< 0.01. (F) P-gp-mediated Src phosphorylation induced by hypotonicity and TGF β1. Representative western blot (upper) and densitometric analysis (lower) showed that phospho-Src (pY^416^) induced by hypotonicity and TGF β1 was abolished by down-regulation of P-gp expression. \*\*: *P*\< 0.01. (G) P-gp binds to Src kinase. (left two panels) P-gp does not bind ClC-3. Immunoblots of co-IP with anti-Flag antibody from extracts of NIH-3T3 cells co-transfected with MDR1/GFP and ClC-3/Flag, probed with antibodies against P-gp or ClC-3 (upper panel). Control experiment with anti-Flag antibody from extracts of NIH-3T3 cells co-transfected with K18/GFP and ClC-3/Flag probed with anti-K18 (centre panel). (Lower panel) Co-IP with anti-GFP antibody from NIH-3T3 cells extract was probed with anti-Src and anti-P-gp. Cells were transfected with human MDR1-GFP vectors.](thnov06p0204g004){#F4}

![**Chloride Channel Blockers Mitigated the Formation of Peritoneal Adhesion by Inhibiting *I*~Cl,vol~ and RVD of Peritoneal Fibroblasts.** (A) Intraperitoneal injection of chloride channel blocker tamoxifen significantly reduced peritoneal adhesion development rate and adhesion grades induced by moderate peritoneal injury in a dose-dependent manner, with an IC~50~ of 3.61 mg/kg (For detailed statistical results, see Table [3](#T3){ref-type="table"}). (B and C) Chloride channel blockers almost completely inhibited *I*~Cl,vol~ of rat AFB. (B) Time course of the Cl^-^ current activated by a hypotonic solution (Hypo, 160 mosmol/l) in AFB and the effect of 20 µM tamoxifen. Iso, isotonic bath solution; Hyper, 47% hypertonic bath solution. (C) Mean current densities in cells treated with tamoxifen (20 µM), DCPIB (20 µM), tariquidar (0.1 µM), or verapamil (100 µM). \*\* *P* \< 0.01. (D) Representative photographic images of peritoneal adhesion in rats. DCPIB (4 mg/kg) significantly inhibited peritoneal adhesion formation. (For detailed statistical results, see Table [4](#T4){ref-type="table"}). (E - G) Chloride channel blockers decreased the RVD capacity of rat AFB. Time course of RVD activated by the hypotonic solution (Hypo) in control (E) and 20 µM tamoxifen-treated cells (F). Iso, cells in isotonic condition. (G) The effects of tamoxifen (20 µM), DCPIB (20 µM), tariquidar (0.1 µM), or verapamil (100 µM) on the RVD capacity of AFB. Data are mean ± SEM, n=3 with \>10 cells.](thnov06p0204g005){#F5}

![**Altering P-gp Expression or Blocking *I*~Cl,vol~ affects Cell Migration and Proliferation.** (A and B) Migratory ability of human and rat AFB overexpressing P-gp and NFB. Confluent monolayers were scratched and then cultured in medium containing 0.5% FCS for 48 h (A). Data shown in (B) are mean ± SEM. (C) Representative photographs of wound-healing motility assays for rat AFB cells transiently transfected with siRNA against MDR1. (D) Average migratory width of AFB cells treated with MDR1 siRNA or inhibitors. Data are mean ± SEM. (E and F) Comparison of proliferative capability between rat AFB and NFB cells (E) and quantification of multiple visual fields (n = 4, F). Bright-field photographs of primary cultured live cells were taken at different times. Dark areas indicate peritoneal adhesion tissue or adjacent normal peritoneum tissue. (G) Growth curve for rat AFB cells transfected with si-MDR1 or treated with different inhibitors. Cells were cultured in 96-well plates in medium with 10% serum. Relative cell numbers were determined by CCK-8 colorimetric assay. Data shown are the results of three independent experiments (mean ± SEM). si-MDR1 transfection and all inhibitors except for tariquidar significantly inhibited the proliferation of AFB cells at day 5 and 7 (*P* \< 0.01 *vs* si-NC).](thnov06p0204g006){#F6}

![**Schematic Diagram Depicting the Proposed Role of P-gp in the Formation of Peritoneal Adhesions following an Abdominal Operation.** In the proposed model, P-glycoprotein mediates postoperative peritoneal adhesion formation in four steps. First, operative injury induces excessive TGF-β1 secretion by macrophages. Second, TGF-β1 up-regulates P-gp expression by enhancing the activity of the MDR1 promoter via the TGF-β1/Smad signaling pathway and histone H3 acetylation. Third, P-gp accelerates activation of volume-activated Cl^-^ channels and cell RVD capability by promoting phosphorylation of ClC-3*via* Src tyrosine kinase. Fourth, increased *I*~Cl,vol~ and cell volume regulation capability accelerates migration and proliferation of fibroblasts, which finally leads to peritoneal adhesion formation.](thnov06p0204g007){#F7}

###### 

The effect of AFB or NFB reinfusion on peritoneal adhesions

  Group                                    n    Grade of adhesion(case)   Average grade   Rate of adhesion \[case(%)\]                  
  ---------------------------------------- ---- ------------------------- --------------- ------------------------------ --- --- ------ --------
  Control ( with mild peritoneal injury)   9    7                         2               0                              0   0   0.22   2(22)
  Reinfusion of NFB                        11   4                         5               2                              0   0   0.82   7(55)
  Reinfusion of AFB^\*^                    11   1                         4               1                              2   3   2.36   10(90)

\* *P* \< 0.05 as compared to the group of rat NFB reinfusion. Adhesion rate describes the presence of an adhesion in any grade.

###### 

The effect of Knockdown of P-gp expression on peritoneal adhesions

  Group                                        n   Grade of adhesion(case)   Average grade   Rate of adhesion \[case(%)\]                 
  -------------------------------------------- --- ------------------------- --------------- ------------------------------ --- --- ----- --------
  Control ( with moderate peritoneal injury)   5   0                         0               0                              1   4   3.8   5(100)
  Transfection of Si-NC                        5   0                         0               0                              2   3   3.6   5(100)
  Transfection of Si-MDR1^\*\*^                5   3                         2               0                              0   0   0.4   2(40)

\*\* *P* \< 0.01 as compared to the Si-NC group.

###### 

The effect of chloride channel blocker tamoxifen on peritoneal adhesions

  ---------------------------------------------------------------------------------------------------
  Group     n   Grade of adhesion(case)   Average grade   Rate of adhesion\                  
                                                          \[case(%)\]                        
  --------- --- ------------------------- --------------- ------------------- --- --- ------ --------
  Control   9   0                         0               4                   5   0   2.56   9(100)

  3mg/kg    9   4                         0               3                   2   0   1.33   5(56)

  5mg/kg    9   3                         2               3                   1   0   1.22   6(67)

  7mg/kg    9   6                         1               2                   0   0   0.56   3(33)
  ---------------------------------------------------------------------------------------------------

Crosstabs, Chi-square test *P* \< 0.01; Spearman\'s correlation analysis, r =-0.55, P \< 0.01.

###### 

The effect of chloride channel blocker DCPIB on peritoneal adhesions

  ------------------------------------------------------------------------------------------------------
  Group         n   Grade of adhesion(case)   Average grade   Rate of adhesion\                 
                                                              \[case(%)\]                       
  ------------- --- ------------------------- --------------- ------------------- --- --- ----- --------
  Control       9   0                         0               1                   3   5   3.4   9(100)

  DCPIB^\*\*^   9   3                         2               4                   0   0   1.1   6(67)
  ------------------------------------------------------------------------------------------------------

\*\*: *P*\< 0.01 *vs* control (Mann-Whitney U test).
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